In vivo Biocompatibility and Toxicity Assessment of a Gentamicin-Loaded Monoolein Gel Intended to Treat Chronic Osteomyelitis

in Journal of Pharmacology & Toxicology (2008), 3(5), 386-393

Biocompatibility and preliminary toxicity of a novel gentamicin-loaded monoolein gel (implant) intended for the local treatment of chronic osteomyelitis were investigated in mice. The mice, randomly ... [more ▼]

Biocompatibility and preliminary toxicity of a novel gentamicin-loaded monoolein gel (implant) intended for the local treatment of chronic osteomyelitis were investigated in mice. The mice, randomly allotted in 3 groups of 10, received respectively a single dose (0.05 mL) of normal saline, monoolein and the gel by subplantar injection. Clinical monitoring and assessment of induced oedema were carried out during 52 days after implantation. A histologic examination of the implantation site was performed at the end of the experiment. Renal and hepatic functions of the implant were also assessed on 52 days post-implantation by using biochemical and histological methods. In mice, no adverse reaction occurred after implantation. Only, a transitional foreign body reaction was observed in mice implanted by the monoolein and the implant. The paw volume of the mice increased within 3 h post-implantation and returned to baseline by 52 days. The liver and kidneys histology at light microscopy and biochemical parameters were similar for all mice. Further investigation is undertaken to detect eventual early damages which could have been resolved with time. Nevertheless, the novel gel is biocompatible and doesn`t show sub-chronic toxicity. [less ▲]

Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides

in Journal of Medicinal Chemistry (2003)

In vitro and in vivo effects of new insulin releasing agents

in Biochemical Pharmacology (2002)

2-N-alkylation of 3-alkylamino-substituted 2H-benzo- and 2H-pyridothiadiazine 1,1-dioxides: from K+ATP channel openers to Ca++ channel blockers?

in Fundamental & Clinical Pharmacology (2002)

2-Alkyl-3-alkylamino-2H-benzo- and pyridothiadiazine 1,1-dioxides: Ca++ channel blockers rather than K+ATP channel openers?

Poster (2001, December 08)

2-N-alkylation of 3-alkylamino-substituted 2H-benzo- and 2H-pyridothiadiazine 1,1-dioxides: from K+ATP channel openers to Ca++ channel blockers?

Poster (2001, November 17)

Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and KATP channel activity

in Journal of Medicinal Chemistry (2001), 44

7-Substituted alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as new analogues of diazoxide: effects on the insulin releasing process in vitro

Poster (2000, March 04)

Les 3-alkylsulfanyl- et 3-alkoxy-4H-1,2,4-benzothiadiazine 1,1-dioxydes structuralement apparentés aux 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxydes en tant qu’activateurs potentiels des canaux potassiques sensibles à l’ATP

Poster (2000, January 28)

7-Substituted alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as new analogues of diazoxide: effects on the insulin releasing process in vitro

in Fundamental & Clinical Pharmacology (2000), 14